Matches in SemOpenAlex for { <https://semopenalex.org/work/W3109374671> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W3109374671 endingPage "75" @default.
- W3109374671 startingPage "73" @default.
- W3109374671 abstract "Glucagon-like peptide 1 (GLP-1) receptor agonists are a safe and effective treatment option for patients with type 2 diabetes (1). Selective activation of the GLP-1 receptor causes glucose-dependent insulin secretion, resulting in a very low risk of hypoglycemia (2). The additional mechanism of slowing gastric emptying has resulted in reliable weight loss with this class of antihyperglycemic medications (3). In addition, multiple agents in this drug class (semaglutide, liraglutide, and dulaglutide) have been proven to reduce the risk of cardiovascular events (4).Furthermore, the possibility of once-weekly dosing for glycemic control in type 2 diabetes has been realized with some GLP-1 receptor agonists (semaglutide, exenatide extended-release, and dulaglutide) as a result of albumin binding that decreases renal clearance and protects against metabolic degradation by the dipeptidyl peptidase-4 enzyme (2). Poor adherence to pharmacologic therapy is well documented in patients with type 2 diabetes and is linked to inadequate glycemic control (based on the American Diabetes Association’s general A1C goal of <7%), and once-weekly dosing has been shown to improve adherence rates (5,6).The use of GLP-1 receptor agonists in practice has become more prominent in recent years, and adverse reactions are generally benign. Most commonly, patients have reported gastrointestinal upset (>10%) and injection-site reactions (>1%) (1,7).General injection-site reactions (e.g., erythema, pain, or rash) have been reported with all of the commercially available GLP-1 receptor agonists (i.e., exenatide, lixisenatide, liraglutide, dulaglutide, and semaglutide) (8–13). However, post-marketing reports have revealed that exenatide extended-release, specifically, may cause more alarming injection-site …" @default.
- W3109374671 created "2020-12-07" @default.
- W3109374671 creator A5006933700 @default.
- W3109374671 creator A5083253724 @default.
- W3109374671 date "2020-11-23" @default.
- W3109374671 modified "2023-10-02" @default.
- W3109374671 title "Injection-Site Nodules Associated With Once-Weekly Subcutaneous Administration of Semaglutide" @default.
- W3109374671 cites W1885890594 @default.
- W3109374671 cites W2067978628 @default.
- W3109374671 cites W2143752451 @default.
- W3109374671 cites W2152984355 @default.
- W3109374671 cites W2176260350 @default.
- W3109374671 cites W2493860075 @default.
- W3109374671 cites W2592545469 @default.
- W3109374671 cites W2891421488 @default.
- W3109374671 cites W917052595 @default.
- W3109374671 doi "https://doi.org/10.2337/ds20-0033" @default.
- W3109374671 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7887535" @default.
- W3109374671 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33627997" @default.
- W3109374671 hasPublicationYear "2020" @default.
- W3109374671 type Work @default.
- W3109374671 sameAs 3109374671 @default.
- W3109374671 citedByCount "2" @default.
- W3109374671 countsByYear W31093746712022 @default.
- W3109374671 countsByYear W31093746712023 @default.
- W3109374671 crossrefType "journal-article" @default.
- W3109374671 hasAuthorship W3109374671A5006933700 @default.
- W3109374671 hasAuthorship W3109374671A5083253724 @default.
- W3109374671 hasBestOaLocation W31093746711 @default.
- W3109374671 hasConcept C126322002 @default.
- W3109374671 hasConcept C134018914 @default.
- W3109374671 hasConcept C17744445 @default.
- W3109374671 hasConcept C199539241 @default.
- W3109374671 hasConcept C2777180221 @default.
- W3109374671 hasConcept C2780765947 @default.
- W3109374671 hasConcept C2781308992 @default.
- W3109374671 hasConcept C2909862629 @default.
- W3109374671 hasConcept C555293320 @default.
- W3109374671 hasConcept C556039675 @default.
- W3109374671 hasConcept C71924100 @default.
- W3109374671 hasConceptScore W3109374671C126322002 @default.
- W3109374671 hasConceptScore W3109374671C134018914 @default.
- W3109374671 hasConceptScore W3109374671C17744445 @default.
- W3109374671 hasConceptScore W3109374671C199539241 @default.
- W3109374671 hasConceptScore W3109374671C2777180221 @default.
- W3109374671 hasConceptScore W3109374671C2780765947 @default.
- W3109374671 hasConceptScore W3109374671C2781308992 @default.
- W3109374671 hasConceptScore W3109374671C2909862629 @default.
- W3109374671 hasConceptScore W3109374671C555293320 @default.
- W3109374671 hasConceptScore W3109374671C556039675 @default.
- W3109374671 hasConceptScore W3109374671C71924100 @default.
- W3109374671 hasIssue "1" @default.
- W3109374671 hasLocation W31093746711 @default.
- W3109374671 hasLocation W31093746712 @default.
- W3109374671 hasLocation W31093746713 @default.
- W3109374671 hasOpenAccess W3109374671 @default.
- W3109374671 hasPrimaryLocation W31093746711 @default.
- W3109374671 hasRelatedWork W1912570827 @default.
- W3109374671 hasRelatedWork W2267959400 @default.
- W3109374671 hasRelatedWork W2748952813 @default.
- W3109374671 hasRelatedWork W2895313197 @default.
- W3109374671 hasRelatedWork W2899084033 @default.
- W3109374671 hasRelatedWork W2914029654 @default.
- W3109374671 hasRelatedWork W2988339773 @default.
- W3109374671 hasRelatedWork W2997605969 @default.
- W3109374671 hasRelatedWork W3216092642 @default.
- W3109374671 hasRelatedWork W4220893377 @default.
- W3109374671 hasVolume "34" @default.
- W3109374671 isParatext "false" @default.
- W3109374671 isRetracted "false" @default.
- W3109374671 magId "3109374671" @default.
- W3109374671 workType "article" @default.